This had been earlier widely-reported -- concerning Zetia®. From DowJones Newswires, then:
. . . .Merck said Monday it has agreed to settle patent litigation surrounding its cholesterol drug Zetia, which will allow a generic manufacturer to begin selling copycat versions of the drug in December 2016, about four months before the scheduled U.S. patent expiration.
Merck's settlement agreement with Glenmark Pharmaceuticals comes more than two weeks after a U.S. judge ruled that some patent claims covering Zetia were invalid, but other claims were valid. . . .
Settled on the eve of trial -- but no Glenmark launch until 2016? Odd. That raises more questions than it answers -- given that Glenmark looked to have the upper-hand, at trial. Maybe someone (hey stock analysts and press people -- hint, here) will ask after this, at Merck's R&D Day, tomorrow morning -- during Q&A.
No comments:
Post a Comment